endpts.com·Apr 8, 2026
A San Diego biotech startup has secured $137 million in Series B funding from prominent investors to enhance the efficacy and reduce the toxicity of antibody-drug conjugates.
The key learning for you is that there is robust investor interest in biotech startups focusing on innovative antibody-drug conjugates (ADCs) aimed at reducing toxicities, as evidenced by a San Diego startup securing a $137 million Series B funding round. This highlights the potential growth and investment opportunities in the ADC space, particularly for small, agile companies with promising technology and strong investor backing.